Dr Elizabeth Iorns
Elizabeth Iorns is a globally recognised scientist, innovator and entrepreneur, who is the co-founder, and current CEO & President (and Chairman of the Board) of Silicon Valley start-up Science Exchange.
Science Exchange is a world-leading marketplace for outsourced scientific research and development – connecting scientists with a network of over 2500 qualified scientific research institutions all over the world, including contract research organisations (CROs) and manufacturers (CMOs), academic labs and government facilities.
Elizabeth and Science Exchange co-founder, Dan Knox (Chief Operating Officer) launched the platform in 2011 with the goal of making the impact of scientific discovery readily available to every organisation on the planet.
The platform has since been credited with transforming the global scientific research industry via the creation of greater connectivity and transparency – enhancing the speed of research, and the growth of scientific knowledge by enabling better access to the world’s scientific expertise.
Elizabeth holds a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK) and was an Assistant Professor at University of Miami’s Miller School of Medicine where she investigated breast cancer development and progression.
of high unmet medical need) and Perception Therapeutics (an organisation dedicated to developing curative gene therapies for inherited retinal diseases). She is also an Advisory Board Member of Meta- Research Innovation Center at Stanford (METRICS).
Elizabeth has been widely recognised for her achievements – including being named one of Goldman Sachs’ ‘100 Most Intriguing Entrepreneurs’; finalist for Scrip’s Executive of the Year Award; Kevin Abosch ‘Women in Tech’ portrait series; Nature Magazine’s ‘Ten People Who Mattered’; ELLE’s Women in Tech; and one of WIRED’s ’50 Women Who Are Changing The World’.
She is regularly featured in the media, as well as being invited to speak at thought-leadership events all over the world.
In addition to her various roles at Science Exchange, Elizabeth is also a co-founder of Reformer Therapeutics (an immuno-oncology company launched in 2018 to develop new therapies for cancers.